Sheetal Hardikar
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (64)
Background: Cell-to-cell adhesion and angiogenesis are hallmarks of cancer. No studies have examined associations of adhesion molecules and angiogenesis biomarkers with clinical outcomes in colorectal cancer. Methods: In presurgery serum from n = 426 patients with colorectal cancer (stage I–III), we investigated associations of CRP, SAA, adhesion molecules (sICAM-1, sVCAM-1), and angiogenesis markers (VEGF-A and VEGF-D) with overall survival (OS), disease-free survival (DFS), and risk of recurrence. We computed HRs and 95% confidence intervals; adjusted for age, sex, BMI, stage, site, and study site, stratified by tumor site in exploratory analyses. Results: N = 65 (15%) were deceased, and 39 patients (14%) had a recurrence after a median follow-up of 31 months. We observed significant associations of biomarkers with OS, DFS, and risk of recurrence on a continuous scale and comparing top to bottom tertile, with HRs ranging between 1.19 and 13.92. CRP was associated with risk of death and recurrence in patients in the top tertile compared with patients in the bottom tertile, for example, risk of recurrence HR Q3-Q1 : 13.92 (1.72–112.56). Significant heterogeneity between biomarkers and clinical outcomes was observed in stratified analysis by tumor site for CRP, SAA, sICAM-1, sVCAM-1, and VEGF-D. VEGF-D was associated with a 3-fold increase in risk of death for rectal cancer (HR log2 : 3.26; 95% CI, 1.58–6.70) compared with no association for colon cancer (HR log2 : 0.78; 95% CI, 0.35–1.73; P heterogenity = 0.01). Conclusions: Adhesion molecules and angiogenesis biomarkers are independent prognostic markers for colorectal cancer, with differences by tumor site. Impact: There is need for tailored treatment for colon and rectal cancer.
Year:
2025
Supplemental Table 3 provides effect estimates for the association of incident diabetes and all-cause mortality among obesity-related cancer survivors and cancer-free individuals, stratified by covariates that did not meet PH assumptions.
Year:
2025
Background: Patients with colorectal cancer commonly suffer from complex psychological distress. Elevated distress may be linked to systemic biomarkers. We investigated associations of biomarkers of inflammation and angiogenesis with cancer-related distress (CTXD) score. Methods: N = 315 patients (stage I–IV) from 2 centers of the ColoCare Study were included: Huntsman Cancer Institute and University of Heidelberg. Biomarkers (e.g., IL6, VEGF-A, VEGF-D) were measured in serum collected pre-surgery and 12 months thereafter. The CTXD overall score and 4 subscales were collected 12 months after surgery and dichotomized to investigate biomarkers as predictors of distress 12 months after surgery; adjusted for age, sex, body mass index, tumor stage, center, and baseline levels of biomarkers. Results: Doubling of IL6 predicted future increased risk of overall distress [odds ratio (OR), 1.20; 95% confidence interval (CI), 1.02–1.41; P = 0.03]. VEGF-A–predicted future increased risk of high family strain (VEGF-A: OR, 1.21; 95% CI, 1.01–1.44; P = 0.04) and VEGF-D was associated with medical and financial demands (OR, 1.34; 95% CI, 1.01–1.74; P = 0.03). Conclusions: This is the first study to show that systemic biomarkers are significantly associated with future CTXD score. Distress was not measured at baseline; we cannot rule out ongoing associations of inflammation and distress throughout treatment versus a direct effect of inflammation on distress. Nonetheless, these data add to evidence that biobehavioral processes interact and that systemic biomarkers are associated with cancer-related distress one year after surgery. Impact: Exercise and diet interventions that lower systemic cytokine levels may impact longer-term CTXD score and improve quality of life of patients with colorectal cancer.
Year:
2025
Supplemental Table 6 provides effect estimates for the association of incident diabetes and cancer-specific mortality among obesity-related cancer survivors, stratified my covariates that did not meet PH assumptions.
Year:
2025
The incidence of colorectal cancer in young adults (age of diagnosis Significance: We investigated whether environmentally driven factors contribute to EOCRC. We observed accelerated epigenetic aging in EOCRC and epigenetic changes associated with chronic inflammation. Tumor immune cell abundances correlated more strongly with microbes in EOCRC than in AOCRC. These data suggest a dysregulation of the immune response in EOCRC, driving chronic inflammation and tissue aging.
Year:
2025
Relationship between microbes and immune cell composition. A, All microbe-genus level abundances (columns) correlated to the deconvolved immune cell abundances (rows), with the strength of the association and its direction indicated by color in the TCGA (top row) and ORIEN (bottom row) datasets. Spearman correlations between the deconvolved abundance of ( B ) activated mast cells or ( C ) neutrophils and microbes in both the TCGA and ORIEN datasets. Concordant associations (significant in both and in the same direction) are shown in green, with select taxa labeled. There were no microbes significantly anticorrelated with activated mast cells or neutrophils.
Year:
2025
Accelerated aging with epigenetic signatures in EOCRC. A, Heatmap was drawn with samples (patients) in the row and CpG sites (probes) in the column. The DNAm values range from 0.0 (completely unmethylated, blue) to 1.0 (completely methylated, red). B, The volcano plot demonstrated differential methylated sites (expressed as β values) between EOCRC and AOCRC groups. △β for each CpG site is defined as β value of (EOCRC – AOCRC). FDR-adjusted P P value P value C, Box plot showed the mean β value of patients with EOCRC and AOCRC was 0.46 ± 0.028 and 0.47 ± 0.027 ( P value = 0.13, two-sample t test), respectively. D, Box plots demonstrated the accelerated aging in EOCRC. The DNAm age acceleration (Δ = methylation age − chronologic age) in EOCRC and AOCRC for all samples is shown. The Δ EOCRC predicted by Horvath, Hannum, and PhenoAge models was 2.1, 18.4, and 32.8 years, respectively. The Δ AOCRC predicted by Horvath, Hannum, and PhenoAge was −14.2, 3.4, and 27.1 years, respectively, with P values of 7.89E−12, 1.48E−08, and 0.17, respectively.
Year:
2025
Intratumoral microbes do not show consistent differences in EOCRC. A, Venn diagram demonstrated partial overlap in microbes among three datasets. The abundances of observed genera that passed stringent quality and contamination filters are shown (ORIEN, n = 353 genera; TCGA, n = 357 genera; and 16S, n = 30 genera), with the best agreement between the two RNA-seq datasets. B, The Bray–Curtis dissimilarity plot showed that RNA-seq–derived microbes were most similar to 16S microbes from the same tumor (paired) and least similar to microbes from adjacent normal tissue from another person (unpaired). C, The comparison of the relative abundance of microbes between the 16S-based dataset and the RNA-seq–based datasets (ORIEN and TCGA). D–F, Volcano plots showed no consistent differences in microbes from RNA-seq–based (TCGA, ORIEN) or 16S-based datasets. No microbes passed the significance threshold in EOCRC. G–I, Effect sizes of the most significant taxa across the three analyses showed no similarities in the AOCRC-enriched microbes.
Year:
2025
Methylation signature validation through GE profiles in EOCRC. A, Integration of the differentially methylated sites with paired RNA-seq showed genes that vary in methylation and transcription. The threshold for the FDR-adjusted P values for differences is 0.05 (FDR P value ≤ 0.05). Highlighted genes in orange indicate significant hypomethylation and expression. B, The canonical pathways involved with DMGs in EOCRC have an FDR-adjusted P value C and D, Bubble chart of pathways based on DEGs in EOCRC from TCGA and ORIEN, highlighting those predicted by methylation alone. The color of the pathways is based on their z -score, and the size of the bubble is correlated with the number of genes from the dataset that overlap each pathway. E, Summary of the analyses to validate the differential methylation, with those supported by all three datasets indicated within the box.
Year:
2025
Background Prior studies have documented that patients with colorectal cancer (CRC) are at an increased risk of cardiovascular disease (CVD). Objectives To examine coronary artery calcium (CAC) as a marker of subclinical atherosclerosis and its association with major adverse cardiovascular events (MACE) in patients with CRC across the cancer treatment trajectory. Methods Adults with newly diagnosed CRC were enrolled in the prospective ColoCare study from 2017 to 2024. CAC was measured from routine diagnostic computed tomography (CT) and positron emission tomography‐CT scans at CRC diagnosis until 5 years post‐diagnosis. Atherosclerosis was defined as the presence of CAC. We used multivariable‐adjusted Fine and Gray models to assess the association between CAC and MACE risk, accounting for competing risks. Results Among 300 CRC patients, the most common CVD risk factors at cancer diagnosis were hypertension (37%), hyperlipidemia (24%), and diabetes (14%). During follow‐up (median = 5.3 years), 75 (25%) individuals experienced MACE: stroke (3%), new/worsening HF (9%), HF exacerbation requiring hospitalization (2%), coronary revascularization (3%), and death (19%). Among individuals with imaging at baseline ( n = 101), 37 (36.6%) had CAC, and statins were not prescribed in 11 (55.0%) patients with moderate/high CAC. For those with serial imaging ( n = 61), 31.1% showed worsening CAC and 3% developed new CAC. Baseline CAC conferred a higher risk of MACE (HR = 4.79; 95% CI: 1.05–21.75, p = 0.04) after accounting for cancer‐related deaths as a competing risk. Conclusions Subclinical atherosclerosis and MACE are common among patients with CRC. Integrating CAC from routine cancer imaging can identify patients who may benefit from cardio‐preventive treatment.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (50)
Shama Karanth
Assistant Professor
University of Florida
Eric Singer
Professor
The Ohio State University Wexner Medical Center
Marc Gunter
International Agency for Research on Cancer
Jiangjiang Zhu
Ohio State University
Garnet Anderson
Fred Hutchinson Cancer Research Center
Aladdin Shadyab
Associate Professor
University of California, San Diego
Gregory Riedlinger
Rutgers Cancer Institute of New Jersey
Nicholas Denko
Professor
Ohio State University
Aik Choon Tan
Senior Director of Data Science
Huntsman Cancer Institute
Fred Tabung
University of South Carolina
Marian Neuhouser
Professor
Fred Hutchinson Cancer Research Center
Fouad Choueiry
Ohio State University
Ning Jin
Associate Proffessor
Ohio State University
Martin D. McCarter
Professor
University of Colorado Anschutz Medical Campus
Carlos HF Chan
Emory University
Karen Syrjala
Fred Hutchinson Cancer Research Center
Matthew Kalady
Professor
Ohio State University
John D. Carpten
City of Hope Comprehensive Cancer Center
Alexandra Ikeguchi
Associate Professor
The University of Texas MD Anderson Cancer Center
Mary Playdon
Assistant Professor
University of Utah
Rebecca Dodd
Assistant Professor
The University of Iowa
Gabriel Tinoco
Associate Professor of Medicine
Ohio State University
Rebecca Seguin-Fowler
Associate Professor
Texas A&M University
Anjun Ma
Assistant Professor
Ohio State University
Claire Jungyoun Han
Ohio State University
Qin Ma
Vice Chair for Research
Ohio State University
Cynthia A. Thomson
-
Yousef Zakharia
Mayo Clinic Arizona
Jean Wactawki-Wende
Dean, Suny Distinguished Professor
University at Buffalo
Adetunji T. Toriola
Washington University School of Medicine
Dan Spakowicz
Assistant Professor
The Ohio State University Comprehensive Cancer Center
Xiaochen Zhang
Assistant Professor
Ohio State University
Scott Summers
Co-Director
University of Utah
Daniel W. Rosenberg
University of Connecticut Health Center
Xiaokui Mo
Research Scientist
Ohio State University
David Shibata
University of Tennessee Health Science Center
Su Yon Jung
University of California, Los Angeles
Ahmad Tarhini
Senior Member, Professor
H Lee Moffitt Cancer Center and Research Institute
William L. Holland
Associate Professor
University of Utah
juhua luo
Professor
Indiana University Bloomington School of Public Health
Griffin Caryotakis
Huntsman Cancer Institute
Caroline Himbert
Assistant Professor
University of Utah Health Huntsman Cancer Institute
Caroline Dravillas
Ohio State University
Yangbo Sun
Assistant Professor
University of Tennessee Health Science Center
Christopher Li
Fred Hutchinson Cancer Research Center
marcia stefanick
Stanford University
Ting-Yuan Cheng
Associate Professor
Ohio State University
YunZhou Liu
Ohio State University
Nazmus Saquib
-
Jennifer Ose
Professorin (W2)
Hochschule Hannover
Make your next move.
Prepare your application
Review drafts before you send them.